Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
VERMA, Subodh; Nitish K DHINGRA; Javed BUTLER; Stefan D ANKER; Joao Pedro FERREIRA et. al.
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Autoři
VERMA, Subodh; Nitish K DHINGRA; Javed BUTLER; Stefan D ANKER; Joao Pedro FERREIRA; Gerasimos FILIPPATOS; James L JANUZZI; Carolyn S P LAM; Naveed SATTAR; Barbara PEIL; Matias NORDABY; Martina BRUECKMANN; Stuart J POCOCK; Faiez ZANNAD a Milton PACKER
VERMA, Subodh; Nitish K DHINGRA; Javed BUTLER; Stefan D ANKER; Joao Pedro FERREIRA; Gerasimos FILIPPATOS; James L JANUZZI; Carolyn S P LAM; Naveed SATTAR; Barbara PEIL; Matias NORDABY; Martina BRUECKMANN; Stuart J POCOCK; Faiez ZANNAD a Milton PACKER. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. LANCET DIABETES & ENDOCRINOLOGY. 2022, roč. 10, č. 1, s. 35-45. ISSN 2213-8587. Dostupné z: https://dx.doi.org/10.1016/S2213-8587(21)00292-8.
@article{2265037, author = {Verma, Subodh and Dhingra, Nitish K and Butler, Javed and Anker, Stefan D and Ferreira, Joao Pedro and Filippatos, Gerasimos and Januzzi, James L and Lam, Carolyn S P and Sattar, Naveed and Peil, Barbara and Nordaby, Matias and Brueckmann, Martina and Pocock, Stuart J and Zannad, Faiez and Packer, Milton}, article_number = {1}, doi = {http://dx.doi.org/10.1016/S2213-8587(21)00292-8}, issn = {2213-8587}, journal = {LANCET DIABETES & ENDOCRINOLOGY}, title = {Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial}, volume = {10}, year = {2022} }
TY - JOUR ID - 2265037 AU - Verma, Subodh - Dhingra, Nitish K - Butler, Javed - Anker, Stefan D - Ferreira, Joao Pedro - Filippatos, Gerasimos - Januzzi, James L - Lam, Carolyn S P - Sattar, Naveed - Peil, Barbara - Nordaby, Matias - Brueckmann, Martina - Pocock, Stuart J - Zannad, Faiez - Packer, Milton PY - 2022 TI - Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial JF - LANCET DIABETES & ENDOCRINOLOGY VL - 10 IS - 1 SP - 35-45 EP - 35-45 SN - 22138587 ER -
VERMA, Subodh; Nitish K DHINGRA; Javed BUTLER; Stefan D ANKER; Joao Pedro FERREIRA; Gerasimos FILIPPATOS; James L JANUZZI; Carolyn S P LAM; Naveed SATTAR; Barbara PEIL; Matias NORDABY; Martina BRUECKMANN; Stuart J POCOCK; Faiez ZANNAD a Milton PACKER. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. \textit{LANCET DIABETES \&{}amp; ENDOCRINOLOGY}. 2022, roč.~10, č.~1, s.~35-45. ISSN~2213-8587. Dostupné z: https://dx.doi.org/10.1016/S2213-8587(21)00292-8.